Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia
Xujie Zhao(St. Jude Children's Research Hospital), Jun J. Yang(St. Jude Children's Research Hospital), Chia‐Lin Wei(Joint Genome Institute), Brandon Smart(St. Jude Children's Research Hospital), Kelly R. Barnett(St. Jude Children's Research Hospital), Jingliao Zhang(St. Jude Children's Research Hospital), Jonathan D. Diedrich(The Barbara Ann Karmanos Cancer Institute), Satoshi Yoshimura(St. Jude Children's Research Hospital), Noemi Reyes(St. Jude Children's Research Hospital), Beisi Xu(St. Jude Children's Research Hospital), Allen Eng Juh Yeoh(National University Cancer Institute, Singapore), Xin Huang(BGI Group (China)), Kristine R. Crews(St. Jude Children's Research Hospital), Daniel Savic(St. Jude Children's Research Hospital), Ping Wang(Xi'an Polytechnic University), Zhenhua Li(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital), Wentao Yang(St. Jude Children's Research Hospital), Marina Konopleva(Albert Einstein College of Medicine)
Cited by 27
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
|Nature|2016|925
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|616